Identification of Molecular Substrate for the Attenuation of Anxiety: A Step Toward the Development of Better Anti-Anxiety Drugs
Anxiety disorders affect some 19 million people in the U.S. alone, costing $46.6 billion, or one third of the nation’s total mental health bill in 1990. Benzodiazepine tranquilizers like the prototypic diazepam are among the most widely used anti-anxiety agents. In addition to their anxiolytic actio...
Saved in:
Main Author: | Uwe Rudolph |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2001-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2001.33 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
AI anxiety: Explication and exploration of effect on state anxiety when interacting with AI doctors
by: Hyun Yang, et al.
Published: (2025-03-01) -
Cognitive Behavioral Therapy of a Generalized Anxiety Disorder Case Comorbid with Health Anxiety
by: Nalan Kara
Published: (2014-08-01) -
Depression and anxiety in glaucoma patients using mono drug therapy vs polydrug therapy
by: Aaiza Tahir, et al.
Published: (2023-06-01) -
Benson’s spiritual relaxation and lavender aromatherapy toward anxiety, sleep quality, and blood pressure
by: Eppy Setiyowati, et al.
Published: (2025-01-01) -
Role of Apolipoprotein E in Anxiety
by: Jacob Raber
Published: (2007-01-01)